|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 June 2001, Vol. 97, No. 11, pp. 3658-3661
BRIEF REPORT
Resting and activated endothelial cells are increased in the
peripheral blood of cancer patients
Patrizia Mancuso,
Alessandra Burlini,
Giancarlo Pruneri,
Aron Goldhirsch,
Giovanni Martinelli, and
Francesco Bertolini
From the Divisions of Hematology-Oncology,
Pathology-Laboratory Medicine, and Medical Oncology, European Institute
of Oncology, Milan, Italy.
Circulating endothelial cells (CECs) were enumerated in 20 healthy
controls and 76 newly diagnosed cancer patients by means of 4-color
flow cytometry. In breast cancer (n = 46) and lymphoma (n = 30)
patients, both resting and activated CECs were increased by 5-fold
(P < .0008 vs control). CECs significantly correlated with plasma levels of vascular cell adhesion molecule-1 and vascular endothelial growth factor. Resting and activated CECs were similar to
healthy controls in 7 lymphoma patients achieving complete remission
after chemotherapy, and activated CECs were found to decrease in 13 breast cancer patients evaluated before and 24 hours after quadrantectomy.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Taylor, J. Rossler, B. Geoerger, A. Laplanche, O. Hartmann, G. Vassal, and F. Farace
High Levels of Circulating VEGFR2+ Bone Marrow-Derived Progenitor Cells Correlate with Metastatic Disease in Patients with Pediatric Solid Malignancies
Clin. Cancer Res.,
July 15, 2009;
15(14):
4561 - 4571.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. SHINGYOJI, S. ANDO, H. NISHIMURA, T. NAKAJIMA, A. ISHIKAWA, M. ITAKURA, T. IIZASA, and H. KIMURA
VEGF in Patients with Non-small Cell Lung Cancer during Combination Chemotherapy of Carboplatin and Paclitaxel
Anticancer Res,
July 1, 2009;
29(7):
2635 - 2639.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Strijbos, J. Kraan, C. H.J. Lamers, S. Sleijfer, and J. W. Gratama
Quantification of Circulating Endothelial Cells by Flow Cytometry
Clin. Cancer Res.,
May 15, 2009;
15(10):
3640 - 3640.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S.-J. Kim, J.-S. Kim, J. Papadopoulos, S. Wook Kim, M. Maya, F. Zhang, J. He, D. Fan, R. Langley, and I. J. Fidler
Circulating Monocytes Expressing CD31: Implications for Acute and Chronic Angiogenesis
Am. J. Pathol.,
May 1, 2009;
174(5):
1972 - 1980.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. M. Smadja, P. Gaussem, L. Mauge, D. Israel-Biet, F. Dignat-George, S. Peyrard, G. Agnoletti, P. R. Vouhe, D. Bonnet, and M. Levy
Circulating Endothelial Cells: A New Candidate Biomarker of Irreversible Pulmonary Hypertension Secondary to Congenital Heart Disease
Circulation,
January 27, 2009;
119(3):
374 - 381.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Donate, G. C. Parry, Y. Shaked, H. Hensley, X. Guan, I. Beck, Z. Tel-Tsur, M. L. Plunkett, M. Manuia, D. E. Shaw, et al.
Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth
Clin. Cancer Res.,
April 1, 2008;
14(7):
2137 - 2144.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. L. G. Bender, P. C. Adamson, J. M. Reid, L. Xu, S. Baruchel, Y. Shaked, R. S. Kerbel, E. M. Cooney-Qualter, D. Stempak, H. X. Chen, et al.
Phase I Trial and Pharmacokinetic Study of Bevacizumab in Pediatric Patients With Refractory Solid Tumors: A Children's Oncology Group Study
J. Clin. Oncol.,
January 20, 2008;
26(3):
399 - 405.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Strijbos, J. Kraan, S. Sleijfer, and J. W. Gratama
Potential Biomarkers in Metastatic Gastrointestinal Stromal Tumors
Clin. Cancer Res.,
October 15, 2007;
13(20):
6244 - 6244.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Ripa, M. Haack-Sorensen, Y. Wang, E. Jorgensen, S. Mortensen, L. Bindslev, T. Friis, and J. Kastrup
Bone Marrow Derived Mesenchymal Cell Mobilization by Granulocyte-Colony Stimulating Factor After Acute Myocardial Infarction: Results From the Stem Cells in Myocardial Infarction (STEMMI) Trial
Circulation,
September 11, 2007;
116(11_suppl):
I-24 - I-30.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Rademaker-Lakhai, L. V. Beerepoot, N. Mehra, S. A. Radema, R. van Maanen, J. S. Vermaat, E. O. Witteveen, C. M. Visseren-Grul, L. Musib, N. Enas, et al.
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C {beta}-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer
Clin. Cancer Res.,
August 1, 2007;
13(15):
4474 - 4481.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Norden-Zfoni, J. Desai, J. Manola, P. Beaudry, J. Force, R. Maki, J. Folkman, C. Bello, C. Baum, S. E. DePrimo, et al.
Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor
Clin. Cancer Res.,
May 1, 2007;
13(9):
2643 - 2650.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Duda, K. S. Cohen, P. Au, D. T. Scadden, C. G. Willett, and R. K. Jain
In Reply
J. Clin. Oncol.,
February 10, 2007;
25(5):
e3 - e5.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. J. Boos, G. Y.H. Lip, and A. D. Blann
Circulating Endothelial Cells in Cardiovascular Disease
J. Am. Coll. Cardiol.,
October 17, 2006;
48(8):
1538 - 1547.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Buckstein, R. S. Kerbel, Y. Shaked, R. Nayar, C. Foden, R. Turner, C. R. Lee, D. Taylor, L. Zhang, S. Man, et al.
High-Dose Celecoxib and Metronomic "Low-dose" Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non-Hodgkin's Lymphoma
Clin. Cancer Res.,
September 1, 2006;
12(17):
5190 - 5198.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Shaked, F. Bertolini, U. Emmenegger, C. R. Lee, and R. S. Kerbel
On the Origin and Nature of Elevated Levels of Circulating Endothelial Cells After Treatment With a Vascular Disrupting Agent
J. Clin. Oncol.,
August 20, 2006;
24(24):
4040 - 4040.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Mehra, M. Penning, J. Maas, L. V. Beerepoot, N. van Daal, C. H. van Gils, R. H. Giles, and E. E. Voest
Progenitor Marker CD133 mRNA Is Elevated in Peripheral Blood of Cancer Patients with Bone Metastases.
Clin. Cancer Res.,
August 15, 2006;
12(16):
4859 - 4866.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S.W. Ng, A. Sparreboom, Y. Shaked, C. Lee, S. Man, N. Desai, P. Soon-Shiong, W. D. Figg, and R. S. Kerbel
Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL-Based Paclitaxel.
Clin. Cancer Res.,
July 15, 2006;
12(14):
4331 - 4338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Mancuso, M. Colleoni, A. Calleri, L. Orlando, P. Maisonneuve, G. Pruneri, A. Agliano, A. Goldhirsch, Y. Shaked, R. S. Kerbel, et al.
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy
Blood,
July 15, 2006;
108(2):
452 - 459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y Wang, H E Johnsen, S Mortensen, L Bindslev, R Sejersten Ripa, M Haack-Sorensen, E Jorgensen, W Fang, and J Kastrup
Changes in circulating mesenchymal stem cells, stem cell homing factor, and vascular growth factors in patients with acute ST elevation myocardial infarction treated with primary percutaneous coronary intervention
Heart,
June 1, 2006;
92(6):
768 - 774.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Ripa, E. Jorgensen, Y. Wang, J. J. Thune, J. C. Nilsson, L. Sondergaard, H. E. Johnsen, L. Kober, P. Grande, and J. Kastrup
Stem Cell Mobilization Induced by Subcutaneous Granulocyte-Colony Stimulating Factor to Improve Cardiac Regeneration After Acute ST-Elevation Myocardial Infarction: Result of the Double-Blind, Randomized, Placebo-Controlled Stem Cells in Myocardial Infarction (STEMMI) Trial
Circulation,
April 25, 2006;
113(16):
1983 - 1992.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. J. van Heeckeren, S. Bhakta, J. Ortiz, J. Duerk, M. M. Cooney, A. Dowlati, K. McCrae, and S. C. Remick
Promise of New Vascular-Disrupting Agents Balanced With Cardiac Toxicity: Is It Time for Oncologists to Get to Know Their Cardiologists?
J. Clin. Oncol.,
April 1, 2006;
24(10):
1485 - 1488.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. G. Duda, K. S. Cohen, E. di Tomaso, P. Au, R. J. Klein, D. T. Scadden, C. G. Willett, and R. K. Jain
Differential CD146 Expression on Circulating Versus Tissue Endothelial Cells in Rectal Cancer Patients: Implications for Circulating Endothelial and Progenitor Cells As Biomarkers for Antiangiogenic Therapy
J. Clin. Oncol.,
March 20, 2006;
24(9):
1449 - 1453.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M. Rigolin, C. Fraulini, M. Ciccone, E. Mauro, A. M. Bugli, C. De Angeli, M. Negrini, A. Cuneo, and G. Castoldi
Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion
Blood,
March 15, 2006;
107(6):
2531 - 2535.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Y. Chong, G. Y.H. Lip, B. Freestone, and A. D. Blann
Increased circulating endothelial cells in acute heart failure: Comparison with von Willebrand factor and soluble E-selectin
Eur J Heart Fail,
March 1, 2006;
8(2):
167 - 172.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. H. Kim, H.-B. Leu, J.-W. Chen, S.-J. Lin, H. C. Ott, D. A. Taylor, F. Bertolini, P. Mancuso, R. S. Kerbel, C. J. Boos, et al.
Circulating Endothelial Progenitor Cells
N. Engl. J. Med.,
December 15, 2005;
353(24):
2613 - 2616.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Holmen, E. Elsheikh, P. Stenvinkel, A. R. Qureshi, E. Pettersson, S. Jalkanen, and S. Sumitran-Holgersson
Circulating Inflammatory Endothelial Cells Contribute to Endothelial Progenitor Cell Dysfunction in Patients with Vasculitis and Kidney Involvement
J. Am. Soc. Nephrol.,
October 1, 2005;
16(10):
3110 - 3120.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. W.L. Yee, A. Hagey, S. Verstovsek, J. Cortes, G. Garcia-Manero, S. M. O'Brien, S. Faderl, D. Thomas, W. Wierda, S. Kornblau, et al.
Phase 1 Study of ABT-751, a Novel Microtubule Inhibitor, in Patients with Refractory Hematologic Malignancies
Clin. Cancer Res.,
September 15, 2005;
11(18):
6615 - 6624.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Shaked, U. Emmenegger, G. Francia, L. Chen, C. R. Lee, S. Man, A. Paraghamian, Y. Ben-David, and R. S. Kerbel
Low-dose Metronomic Combined with Intermittent Bolus-dose Cyclophosphamide Is an Effective Long-term Chemotherapy Treatment Strategy
Cancer Res.,
August 15, 2005;
65(16):
7045 - 7051.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Shaked, D. Cervi, M. Neuman, L. Chen, G. Klement, C. R. Michaud, M. Haeri, B. J. Pak, R. S. Kerbel, and Y. Ben-David
The splenic microenvironment is a source of proangiogenesis/inflammatory mediators accelerating the expansion of murine erythroleukemic cells
Blood,
June 1, 2005;
105(11):
4500 - 4507.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Beaudry, J. Force, G. N. Naumov, A. Wang, C. H. Baker, A. Ryan, S. Soker, B. E. Johnson, J. Folkman, and J. V. Heymach
Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity
Clin. Cancer Res.,
May 1, 2005;
11(9):
3514 - 3522.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Rabascio, E. Muratori, P. Mancuso, A. Calleri, V. Raia, T. Foutz, S. Cinieri, G. Veronesi, G. Pruneri, P. Lampertico, et al.
Assessing Tumor Angiogenesis: Increased Circulating VE-Cadherin RNA in Patients with Cancer Indicates Viability of Circulating Endothelial Cells
Cancer Res.,
June 15, 2004;
64(12):
4373 - 4377.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Park, R. S. Kerbel, G. J. Kelloff, J. C. Barrett, B. A. Chabner, D. R. Parkinson, J. Peck, R. W. Ruddon, C. C. Sigman, and D. J. Slamon
Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development
Clin. Cancer Res.,
June 1, 2004;
10(11):
3885 - 3896.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. F. V. Woude, G. J. Kelloff, R. W. Ruddon, H.-M. Koo, C. C. Sigman, J. C. Barrett, R. W. Day, A. P. Dicker, R. S. Kerbel, D. R. Parkinson, et al.
Reanalysis of Cancer Drugs: Old Drugs, New Tricks
Clin. Cancer Res.,
June 1, 2004;
10(11):
3897 - 3907.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J Makin, A. D Blann, N. A.Y Chung, S. H Silverman, and G. Y.H Lip
Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells: Relationship with von Willebrand factor and tissue factor
Eur. Heart J.,
March 1, 2004;
25(5):
371 - 376.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. V. Beerepoot, N. Mehra, J. S. P. Vermaat, B. A. Zonnenberg, M. F. G. B. Gebbink, and E. E. Voest
Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients
Ann. Onc.,
January 1, 2004;
15(1):
139 - 145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Bertolini, S. Paul, P. Mancuso, S. Monestiroli, A. Gobbi, Y. Shaked, and R. S. Kerbel
Maximum Tolerable Dose and Low-Dose Metronomic Chemotherapy Have Opposite Effects on the Mobilization and Viability of Circulating Endothelial Progenitor Cells
Cancer Res.,
August 1, 2003;
63(15):
4342 - 4346.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Capillo, P. Mancuso, A. Gobbi, S. Monestiroli, G. Pruneri, C. Dell'Agnola, G. Martinelli, L. Shultz, and F. Bertolini
Continuous Infusion of Endostatin Inhibits Differentiation, Mobilization, and Clonogenic Potential of Endothelial Cell Progenitors
Clin. Cancer Res.,
January 1, 2003;
9(1):
377 - 382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Monestiroli, P. Mancuso, A. Burlini, G. Pruneri, C. Dell'Agnola, A. Gobbi, G. Martinelli, and F. Bertolini
Kinetics and Viability of Circulating Endothelial Cells As Surrogate Angiogenesis Marker in an Animal Model of Human Lymphoma
Cancer Res.,
June 1, 2001;
61(11):
4341 - 4344.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
